With its lead migraine treatment in late-stage trials, TriGemX Bio has raised $94.0M from investors including The Column Group, TCGX, and Viking Global Investors. The biotech company, founded by world-leading neuroscientists, is developing innovative medicines by leveraging unique insights into neural signaling pathways.
TriGemX Bio's pipeline focuses on delivering an effective, easy-to-use, first-in-class medication for migraine. Its lead asset, Elismetrep, is currently in Phase 3 for the acute treatment of the condition, underscoring the company's advanced progress in the field.





.png&w=3840&q=75)








